154 related articles for article (PubMed ID: 3124452)
1. Synergism between alpha-interferon and interleukin-2-activated killer cells: in vitro studies.
Di Raimondo F; LaPushin R; Hersh EM
Acta Haematol; 1987; 78 Suppl 1():77-83. PubMed ID: 3124452
[TBL] [Abstract][Full Text] [Related]
2. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
3. Alpha-interferon and lymphokine-activated killer cells in hairy cell leukemia.
Griffiths SD; Cawley JC
Leukemia; 1988 Jun; 2(6):377-81. PubMed ID: 3374170
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of recombinant interferons alpha, beta, and gamma on induction of human lymphokine (IL-2)-activated killer activity.
Sone S; Utsugi T; Nii A; Ogura T
J Natl Cancer Inst; 1988 May; 80(6):425-31. PubMed ID: 3130488
[TBL] [Abstract][Full Text] [Related]
5. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
6. Interferon is able to reduce tumor cell susceptibility to human lymphokine-activated killer (LAK) cells.
Grönberg A; Ferm M; Tsai L; Kiessling R
Cell Immunol; 1989 Jan; 118(1):10-21. PubMed ID: 2463094
[TBL] [Abstract][Full Text] [Related]
7. Protection of cultured human monocytes from lymphokine-activated killer-mediated lysis by IFN-gamma.
Blanchard DK; Djeu JY
J Immunol; 1988 Dec; 141(11):4067-73. PubMed ID: 2460557
[TBL] [Abstract][Full Text] [Related]
8. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S
Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779
[TBL] [Abstract][Full Text] [Related]
9. Lymphokine activated killer (LAK) cells in antibody dependent cellular cytotoxicity (ADCC) using MAb 17-1A: a combination of potential usefulness in tumor therapy.
Masucci G; Wersäll P; Nielsen J; Nielsen HK; Wigzell H; Mellstedt H
Hybridoma; 1989 Oct; 8(5):507-16. PubMed ID: 2807310
[TBL] [Abstract][Full Text] [Related]
10. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI
J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355
[TBL] [Abstract][Full Text] [Related]
11. Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells.
Jewell AP; Worman CP; Giles FJ; Goldstone AH; Lydyard PM
Leuk Lymphoma; 1992 Aug; 7(5-6):473-80. PubMed ID: 1362916
[TBL] [Abstract][Full Text] [Related]
12. [The role of interferons in neuroblastoma. 2: Immunomodulatory effects].
Handgretinger R; Bruchelt G; Daurer B; Lang P; Dopfer R; Reisfeld RA; Treuner J; Niethammer D
Klin Padiatr; 1990; 202(4):206-11. PubMed ID: 2118581
[TBL] [Abstract][Full Text] [Related]
13. Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines.
Gazit Z; Weiss DW; Shouval D; Yechezkeli M; Schirrmacher V; Notter M; Walter J; Kedar E
Cancer Immunol Immunother; 1992; 35(2):135-44. PubMed ID: 1596937
[TBL] [Abstract][Full Text] [Related]
14. Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity.
Brooks B; Rees RC
Clin Exp Immunol; 1988 Nov; 74(2):162-5. PubMed ID: 3265652
[TBL] [Abstract][Full Text] [Related]
15. Interferon-gamma-induced alterations of monocyte susceptibility to lysis by autologous lymphokine-activated killer (LAK) cells.
Djeu JY; Blanchard DK
Int J Cancer; 1988 Sep; 42(3):449-54. PubMed ID: 3138195
[TBL] [Abstract][Full Text] [Related]
16. Combination treatment of 2-chlorodeoxyadenosine and type I interferon on hairy cell leukemia-like cells: cytotoxic effect and MHC-unrestricted killer cell regulation.
Reiter Z; Tomson S; Ozes ON; Taylor MW
Blood; 1993 Apr; 81(7):1699-708. PubMed ID: 8096405
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effects of phorbol ester and interferon-alpha: target cell class I HLA antigen expression and resistance to natural killer and lymphokine-activated killer cell-mediated cytolysis.
Migita K; Eguchi K; Akiguchi I; Ida H; Kawakami A; Ueki Y; Kurata A; Fukuda T; Nagataki S
Cell Immunol; 1991 May; 134(2):325-35. PubMed ID: 2021973
[TBL] [Abstract][Full Text] [Related]
18. Lymphokine-activated killer (LAK) cells: interferon-gamma synergizes with interleukin-2 to induce LAK cytotoxicity in homogeneous leukemic preparations.
Kaufmann Y; Davidsohn J; Levanon M; Icekson I; Revel M; Ramot B
Clin Immunol Immunopathol; 1991 Feb; 58(2):278-88. PubMed ID: 1898716
[TBL] [Abstract][Full Text] [Related]
19. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.
Owen-Schaub LB; Gutterman JU; Grimm EA
Cancer Res; 1988 Feb; 48(4):788-92. PubMed ID: 3257408
[TBL] [Abstract][Full Text] [Related]
20. Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1.
Espevik T; Figari IS; Ranges GE; Palladino MA
J Immunol; 1988 Apr; 140(7):2312-6. PubMed ID: 3280680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
